Results 61 to 70 of about 820 (140)

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations

Journal of Blood Medicine, 2019
Koji Yada, Keiji NogamiDepartment of Pediatrics, Nara Medical University, Kashihara, Nara, JapanAbstract: Emicizumab is a factor (F)VIIIa-mimicking bispecific antibody recognizing FIXa and FX molecules.
Yada K, Nogami K
doaj  

Benign by design: A paradigm shift in cosmetic ingredient development

International Journal of Cosmetic Science, EarlyView.
Benign by design strategies enable the creation of biodegradable cosmetic ingredients, reducing environmental persistence while maintaining the intended biological activity. This work compiles design rules and tools to guide the development of more sustainable molecules for the cosmetics industry.
Sandra Mota, Klaus Kümmerer, Isabel Martins de Almeida, Emília Sousa   +3 more
wiley   +1 more source

Thromboelastography Profiles of Hemophilia A patients on Emicizumab

, 2022
Emicizumab is a new monoclonal antibody developed to dtreat people with Hemophilia A, especially those with antibodies. However, breakthrough bleeding can still occur in patients taking Emicizumab.
VanZweden, Daniel J, Chitlur, Meera, Stadler, Charity J   +2 more
core  

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)

Research and Practice in Thrombosis and Haemostasis, 2022
Background Emicizumab is a subcutaneously administered humanized, bispecific, monoclonal antibody approved for prophylaxis in people with hemophilia A. Methods HAVEN 5 (NCT03315455) is a randomized, open‐label, phase 3 study of individuals aged ≥12 years
Renchi Yang, Shujie Wang, Xuefeng Wang, Jing Sun, Ampaiwan Chuansumrit, Jianfeng Zhou, Christophe Schmitt, Wanling Hsu, Jeffrey Xu, Lindong Li, Tiffany Chang, Xielan Zhao   +11 more
doaj   +1 more source

A Comprehensive Disproportionality Analysis of Drug‐Related Head Injury Reports Using the FAERS Database

Brain and Behavior, Volume 16, Issue 6, June 2026.
ABSTRACT Objective This study aimed to identify and characterize drugs associated with reports of head injury through a comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database. Methods A retrospective disproportionality analysis was conducted on FAERS reports from 2004 to 2023.
Jiaqi Guo, Luming Wei, Junfeng Liu, Jimei Zhang, He Wang, Wanjun Lu   +5 more
wiley   +1 more source

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

New England Journal of Medicine, 2017
Emicizumab (ACE910) bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in persons with hemophilia A. This phase 3, multicenter trial assessed once-weekly subcutaneous emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors.We enrolled participants who were 12 years of ...
Johannes, Oldenburg, Johnny N, Mahlangu, Benjamin, Kim, Christophe, Schmitt, Michael U, Callaghan, Guy, Young, Elena, Santagostino, Rebecca, Kruse-Jarres, Claude, Negrier, Craig, Kessler, Nancy, Valente, Elina, Asikanius, Gallia G, Levy, Jerzy, Windyga, Midori, Shima   +14 more
openaire   +6 more sources

Inhibitory hemophilia: contemporary treatment with emicizumab. Considerations for pediatric practice [PDF]

Introduction. This article provides an overview of current knowledge and global experience regarding the use of emicizumab, with a focus on its specific considerations in pediatric practice.
Agachi, Dorina, Țurea, Valentin, Eșanu, Galina   +2 more
core   +1 more source

In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients

, 2022
BACKGROUND: Heparin management in hemophilia A (HA) patients with a factor VIII (FVIII) inhibitor can be challenging due to severe activated clotting time (ACT) prolongations. It is important to better understand the impact of emicizumab, a FVIII mimetic
Tanaka, Kenichi A, Henderson, Reney, Kiruphagaran Thangaraju, Upendra Katneni, Morita, Yoshihisa, Katneni, Upendra, Mazzeffi, Michael A, Erik Strauss, Buehler, Paul W, Yoshihisa Morita, Strauss, Erik, Michael A. Mazzeffi, Kenichi A. Tanaka, Paul W. Buehler, Thangaraju, Kiruphagaran, Reney Henderson   +15 more
core   +1 more source

Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors’ Organisation

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab prophylaxis is restricted to severe hemophilia A in the UK. Treatment choice and safety remain a matter of debate. Objectives: This study was conducted to investigate factors influencing treatment choice, continued use, safety, and
Caroline Wall, Hua Xiang, Ben Palmer, Pratima Chowdary, Peter W. Collins, Richard Gorman, Mary Matthias, Charles Percy, Paul Sartain, Susan Shapiro, David Stephensen, Kate Talks, Charles R.M. Hay   +12 more
doaj   +1 more source

Myeloid Cell Function and Cytokine Profiles in Paediatric Haemophilia A: Insights From FVIII and Emicizumab Prophylaxis

Journal of Cellular and Molecular Medicine, Volume 30, Issue 11, June 2026.
ABSTRACT Haemophilia A (HA) is an X‐linked bleeding disorder caused by factor VIII (FVIII) deficiency, treated with FVIII infusions or, more recently, Emicizumab subcutaneously. Although Emicizumab is safe and effective, FVIII is still required for severe bleeding, trauma, or surgery, and few studies have compared these prophylactic options in ...
Alessia Cottonaro, Saicharan Akula, Berardino Pollio, Irene Ricca, Tiziano Martini, Roberto Albiani, Jacopo Agnelli Giacchello, Patrizia Sciancalepore, Roberto Santi, Antonia Follenzi, Simone Merlin   +10 more
wiley   +1 more source